

30 November 2023

Manager, Company Announcements
ASX Limited
Level 4
20 Bridge Street
SYDNEY NSW 2000

Via E-Lodgement

Dear Sir/Madam

**Mayne Pharma Group Limited
Annual General Meeting Results**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), we advise details of the results of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

All resolutions were approved. As a result of Resolution 3, Anne Lockwood has been appointed as a Director of Mayne Pharma Group Limited with effect from the end of the Annual General Meeting.

As more than 25% of the votes cast on Resolution 4 were against the adoption of the FY23 Remuneration Report, this constitutes a 'first strike' for the purposes of the Corporations Act 2001 (Cth).

Yours faithfully,
Mayne Pharma Group Limited



Authorised for release by
Laura Loftus
Company Secretary

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Re-election of Mr Frank Condella	Ordinary	43,168,545 98.33%	432,465 0.99%	297,539 0.68%	54,419	44,269,593 99.03%	432,465 0.97%	54,419	Carried
2 Re-election of Mr Patrick Blake	Ordinary	43,166,063 98.34%	433,201 0.98%	295,785 0.68%	57,919	44,265,357 99.03%	433,201 0.97%	57,919	Carried
3 Election of Ms Anne Lockwood	Ordinary	43,051,073 98.20%	493,338 1.12%	295,785 0.68%	114,272	44,150,367 98.89%	493,338 1.11%	114,272	Carried
4 Adoption of Remuneration Report	Ordinary	28,062,065 65.23%	14,658,927 34.08%	293,916 0.69%	152,430	28,967,744 66.28%	14,735,937 33.72%	159,236	Carried
5 Issue of Short-Term Incentive grant of Restricted Stock Unit Performance Rights and Long-Term Incentive grant of Performance Rights under the Employee Performance Rights and Option Plan (PROP) to the CEO and MD	Ordinary	29,652,463 67.76%	13,820,372 31.58%	286,690 0.66%	194,943	30,713,763 68.94%	13,838,569 31.06%	205,645	Carried
6 Appointment of BDO Audit Pty Ltd as Auditor	Ordinary	43,306,492 98.82%	218,539 0.50%	297,235 0.68%	132,202	44,405,989 99.51%	218,539 0.49%	133,449	Carried
7 Extension of On-Market Share Buy Back	Ordinary	43,447,374 99.00%	140,780 0.32%	295,635 0.68%	70,679	44,541,475 99.68%	140,780 0.32%	75,722	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.



Mayne Pharma Group Limited
 ABN 76 115 832 963
maynepharma.com

T +61 8 8209 2666 **F** +61 8 8281 0284
 1538 Main North Road, Salisbury South, SA 5106 Australia
 PO Box 700, Salisbury, SA 5108 Australia